Glaucoma Watch prev next
Feb 29 2008
Oxidative Stress in Glaucoma: A Burden of Evidence
This comprehensive article is a synthesis of many studies that provide current evidence of the role of oxidative stress in glaucoma. The authors addressed three modes of experimentation: human, animal and in vitro. Evidence suggests that oxidative free radicals, whether induced by ischemia or elevation of IOP, result in apoptosis and death of retinal ganglion cells and progressive vision loss in glaucoma. Taken together, the studies found that neuroprotection can be achieved through antioxidants, flavonoids and astrocyte cocultures. The synthesis included 121 references and was conducted by DO/PhD candidate Domalapalli Maneesh Kumar and Neeraj Agarwal, PhD, and can be found in the May 2007 edition of Journal of Glaucoma.
The human trials section included the work of Gherghel et al, Yildrim et al, and Ferreira et al which demonstrated that enzymatic and nonenzymatic indicators in serum may assess oxidative burden. They found that mechanisms that are designed to combat oxidative stress such as Glutathione peroxidase to be nearly three times greater in glaucoma patients, indicating the high levels of oxidative burden. The higher levels of oxidative stress in serum indicate that retinal damage can be an ocular manifestation of underlying systemic conditions. The work of Izzotti et al and Sacca et al revealed that if the oxidative stress in the anterior chamber of the eye is great enough, it can directly damage the DNA of the trabecular meshwork and upset the regulation of IOP, potentially contributing to the mechanisms of glaucoma.
The animal studies segment included the work of Moreno et al, where induced chronic elevation of IOP in rats led to a dramatic decrease in antioxidant defense systems and increased retinal ganglion cell death. Tezal et al studied the oxidative effect on retinal proteins, demonstrating that continued oxidative stress modifies active binding sites of GAPDH leading to nuclear accumulation of GAPDH bound DNA. It has been shown that accumulation of GAPDH bound DNA is actually a propagator of neuronal apoptosis in Alzheimer, Huntington and Parkinson degenerative diseases. In hypertensive eyes there was a higher sensitivity to oxidative damage, disrupting the conversion of glutamate to glutamine primarily located in the Muller cell layer of the retina. Dreyer et al found that elevated intravitreal glutamate, a neurotoxin at high levels, directly correlates with the apoptosis of retinal ganglion cells in glaucoma. Nucci et al went further and demonstrated that acute elevation of IOP increases glutamate levels in rats with subsequent nerve loss. Cummings et al used mass spectroscopy to further identify specific proteins responsible for oxidative damage in glaucoma, opening the doorway for specific therapies to be developed.
The in-vitro studies were consistent with results from the animal and human trials, and yielded additional information as well. Maher et al, in his RGC-5 study, found that in vitro treatment of retinal ganglion cells with flavonoids could be used to prevent the effects of oxidative stress and that these flavonoids induced the synthesis of proteins which have antioxidative effects and thus were neuroprotectant. In addition, in vitro retinal ganglion cells that were subjected to high levels of pressure, up to 70mm Hg, resulted in apoptosis but could be reversed by interleukin-6. A study by Lucius and Sievers examined postnatal primary retinal ganglion cells that experienced axonal degeneration by exposure to oxidative radicals. These ganglion cells were then treated with vitamins E and C and astrocyte cocluture, resulting in stoppage of axonal loss; further treatment actually improved the number and length of neurites from the explanted retina. The study concluded that endogenous astrocytes can protect retinal ganglion cell destruction by its neurotrophic factors.
The studies noted above, along with many others cited in the article, provide compelling and evidence of the role that oxidative stresses play in glaucoma. However, the actual cause of glaucomatous ganglion cell loss is still mysterious. There are many studies cited in the review that show that glutamate levels in glaucoma patients remain unchanged and that oxidative stresses are not the primary insult inducing retinal ganglion cell death. Thus, the actual mechanism of retinal ganglion cell death remains unproven. Despite this, the data regarding oxidative stresses must be considered. And in light of these studies, the article suggests that a proposed solution to nerve loss in glaucoma and visual field defects is neuroprotection through antioxidant treatment, flavonoids or endogenous astrocyte cocultures.